Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $11.36

Shares of Vor Biopharma Inc. (NYSE:VOR) have received an average recommendation of “Buy” from the seven ratings firms that are covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $11.36.

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Vor Biopharma in a research report on Monday, December 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th.

Vor Biopharma Price Performance

NYSE:VOR opened at $1.00 on Friday. The firm’s 50-day moving average price is $1.33 and its 200-day moving average price is $1.01. The company has a market capitalization of $68.67 million, a PE ratio of -0.61 and a beta of -0.40. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds have recently bought and sold shares of VOR. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Vor Biopharma in the 4th quarter worth about $33,000. Rosalind Advisors Inc. bought a new position in Vor Biopharma in the 3rd quarter worth about $54,000. Virtu Financial LLC bought a new position in Vor Biopharma in the 4th quarter worth about $60,000. XTX Topco Ltd bought a new position in Vor Biopharma during the 4th quarter valued at about $80,000. Finally, Trustees of Columbia University in the City of New York bought a new position in Vor Biopharma during the 4th quarter valued at about $102,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.